Quant (QNT) Rockets 75% Today as Major Banking Catalyst Fuels 180% Weekly Rally
During a relatively calm weekend trading session in which most larger-cap cryptocurrencies have remained sideways, Quant’s QNT has gone on a tear, skyrocketing by 75% in the past 24 hours alone to over $180.
A major US banking partnership appears to be the most evident catalyst, although on-chain data shows activity began heating up well before the announcement was made public.
Why Is QNT Soaring?
Interestingly, the biggest fundamental development didn’t come in the past 24 hours. It was announced on September 24 when The Clearing House selected Quant to power its On-Chain Money Initiative. The crypto project will provide the interoperability, orchestration, and transaction-management layer for the planned network, allowing financial institutions to clear and settle tokenized deposits while connecting with existing payment infrastructure, including the RTP and CHIPS networks.
Both parties expect to launch the system to participating institutions in the first half of 2027. The scale involved helps explain why this announcement attracted so much attention. The Clearing House says its US payment networks clear and settle more than $2 trillion every day, across wire, ACH, check-image, and real-time payments.
However, the activity around Quant and its native token started to pick up over a week before the partnership made the news. Santiment Intelligence said that active addresses exceeded 870 every day between September 16 and 23, whereas they had not topped 792 during the first half of the month.
New addresses were also running at approximately 1.8 times their earlier September weekday average. After the announcement, though, active addresses exploded to 2,064 on September 24, which marked the highest level in nearly a year. QNT’s price skyrocketed by 27% that day.
How High, QNT?
There’s no way to sugarcoat what happened to QNT’s price in the past day and week. The asset is up by 75% since this time yesterday and by a whopping 185% weekly. It currently trades at $180 after briefly topping $190 earlier today.
Crypto Patel, who outlined the significance of the $115 support recently, noted that QNT has reached a couple of his big targets. However, he warned that investors should not FOMO in and start buying now, trying to catch the next wave up.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
